Skip to content

Differing predictors of resistance to atazanavir/ritonavir or Kaletra identified

Cost of treatment and care becoming sensitive issue for UK as NHS faces spending slow-down

Next generation NRTI, DFC (Reverset) discontinued due to safety concerns

Ultra-sensitive test reveals highly variable patterns of NNRTI resistance decay

Risk of disease progression linked to CD4 cell count and HIV DNA level during primary infection

Growth hormone production reduced in HIV-positive men with fat redistribution

Variation in gene linked to risk of resistance after stopping efavirenz treatment

BHIVA: One in five diagnosed HIV-positive with low CD4 counts not on treatment in 2004

BHIVA: Kaletra monotherapy has benefits in clinical practice for highly treatment-experienced